Key result
BNP and NT-pro-BNP are sensitive markers for many forms of heart disease, with evolving clinical uses in diagnosis and treatment.
This review highlights the biological actions of natriuretic peptides and their clinical utility as sensitive biomarkers for heart disease and potential therapeutic agents in acute decompensated heart failure.
Supports BNP/NT-proBNP use in pediatric heart disease; leaves open optimal thresholds and therapeutic roles pending prospective trials.
Background: The natriuretic peptides are a family of structurally similar peptides. Atrial natriuretic peptide and B-type natriuretic peptide (BNP) are cardiac hormones secreted from the heart in response to cardiac chamber distention. Their biological actions include diuresis, natriuresis and vasodilatation, as well as suppression of the renin-angiotensin-aldosterone and endothelin systems. The hemodynamic actions of the secreted natriuretic peptide unload the heart in response to increased intravascular volume. Knowledge regarding the biological actions of the natriuretic peptides continues to evolve into clinical use. A synthetic BNP analogue has shown a beneficial short-term effect in acute decompensated heart failure, while plasma levels of natriuretic peptides have been shown to be elevated in patients with heart disease. Conclusions: BNP and the N-terminal segment of its prohormone, NT-pro-BNP, are very sensitive markers for many forms of heart disease. Future research will likely allow greater use of these peptides in the diagnosis and treatment of heart diseases in adults and children.
No takes yet. Share an insight, caveat, or question.
Amiram Nir (2007) conducted a review in Heart disease. Natriuretic peptides was evaluated. BNP and NT-pro-BNP are sensitive markers for many forms of heart disease, with evolving clinical uses in diagnosis and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: